BD PharmingenTM Purified Rat Anti-Human IL-2

Description

Expression of IL-2 by stimulated CD3+ human PBMC. Human PBMCs were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. #P-8139 and calcium ionophore A23187 500-100 ng/ml final concentration; Sigma, Cat. #C-9275 in the presence of BD GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMCs were stained with PE-Cy5-anti-CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with 0.25 mug of FITC-rat anti-human IL-2 antibody Cat. No. 554565 using Pharmingens staining protocol left panel . To demonstrate specificity of staining, the binding of FITC-MQ1-17H12 was blocked by the preincubation of the fluorochrome - conjugated antibody with recombinant human IL-2 10 ng/ml final concentration; Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with Purified Rat Anti-Human IL-2 5.0 mug, Cat. No. 554563; right panel prior to staining with the FITC-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody blocking right panel specificity controls. Expression of IL-2 by stimulated CD3+ human PBMC. Human PBMCs were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. #P-8139 and calcium ionophore A23187 500-100 ng/ml final concentration; Sigma, Cat. #C-9275 in the presence of BD GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMCs were stained with PE-Cy5-anti-CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with 0.25 mug of FITC-rat anti-human IL-2 antibody Cat. No. 554565 using Pharmingens staining protocol left panel . To demonstrate specificity of staining, the binding of FITC-MQ1-17H12 was blocked by the preincubation of the fluorochrome - conjugated antibody with recombinant human IL-2 10 ng/ml final concentration; Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with Purified Rat Anti-Human IL-2 5.0 mug, Cat. No. 554563; right panel prior to staining with the FITC-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody blocking right panel specificity controls. Expression of IL-2 by stimulated CD3+ human PBMC. Human PBMCs were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. #P-8139 and calcium ionophore A23187 500-100 ng/ml final concentration; Sigma, Cat. #C-9275 in the presence of BD GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMCs were stained with PE-Cy5-anti-CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with 0.25 mug of FITC-rat anti-human IL-2 antibody Cat. No. 554565 using Pharmingens staining protocol left panel . To demonstrate specificity of staining, the binding of FITC-MQ1-17H12 was blocked by the preincubation of the fluorochrome - conjugated antibody with recombinant human IL-2 10 ng/ml final concentration; Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with Purified Rat Anti-Human IL-2 5.0 mug, Cat. No. 554563; right panel prior to staining with the FITC-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody blocking right panel specificity controls. Show More Expression of IL-2 by stimulated CD3+ human PBMC. Human PBMCs were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. #P-8139 and calcium ionophore A23187 500-100 ng/ml final concentration; Sigma, Cat. #C-9275 in the presence of BD GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMCs were stained with PE-Cy5-anti-CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with 0.25 mug of FITC-rat anti-human IL-2 antibody Cat. No. 554565 using Pharmingens staining protocol left panel . To demonstrate specificity of staining, the binding of FITC-MQ1-17H12 was blocked by the preincubation of the fluorochrome - conjugated antibody with recombinant human IL-2 10 ng/ml final concentration; Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with Purified Rat Anti-Human IL-2 5.0 mug, Cat. No. 554563; right panel prior to staining with the FITC-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody blocking right panel specificity controls. Show More Expression of IL-2 by stimulated CD3+ human PBMC. Human PBMCs were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. #P-8139 and calcium ionophore A23187 500-100 ng/ml final concentration; Sigma, Cat. #C-9275 in the presence of BD GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMCs were stained with PE-Cy5-anti-CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with 0.25 mug of FITC-rat anti-human IL-2 antibody Cat. No. 554565 using Pharmingens staining protocol left panel . To demonstrate specificity of staining, the binding of FITC-MQ1-17H12 was blocked by the preincubation of the fluorochrome - conjugated antibody with recombinant human IL-2 10 ng/ml final concentration; Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with Purified Rat Anti-Human IL-2 5.0 mug, Cat. No. 554563; right panel prior to staining with the FITC-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody blocking right panel specificity controls. Expression of IL-2 by stimulated CD3+ human PBMC. Human PBMCs were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. #P-8139 and calcium ionophore A23187 500-100 ng/ml final concentration; Sigma, Cat. #C-9275 in the presence of BD GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMCs were stained with PE-Cy5-anti-CD3 Cat. No. 555334 , fixed, permeabilized, and then stained with 0.25 mug of FITC-rat anti-human IL-2 antibody Cat. No. 554565 using Pharmingens staining protocol left panel . To demonstrate specificity of staining, the binding of FITC-MQ1-17H12 was blocked by the preincubation of the fluorochrome - conjugated antibody with recombinant human IL-2 10 ng/ml final concentration; Cat. No. 554603; middle panel , and by preincubation of the fixed/permeabilized cells with Purified Rat Anti-Human IL-2 5.0 mug, Cat. No. 554563; right panel prior to staining with the FITC-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking middle panel and unlabeled antibody blocking right panel specificity controls.